YAP1 and hepatocellular carcinoma: However, when this pathway is disrupted, leading to the aberrant activation of YAP/TAZ, it has been associated with several cancers, including non-small cell lung cancer, gastric cancer, hepatocellular carcinoma, renal cell carcinoma, colorectal cancer, leukemia, and breast cancer.